Heparin Or Derivative Patents (Class 536/21)
  • Patent number: 10072039
    Abstract: The present invention provides improved processes of preparing Fondaparinux sodium comprising converting a compound of formula ABCDE4 to Fondaparinux sodium at a reaction pH of no more than about 9.0. In some embodiments, the intermediates for the synthesis of Fondaparinux sodium, are also provided.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: September 11, 2018
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Lung-Huang Kuo, Shang-Hong Chen, Li-Ting Wang, Wen-Li Shih, Yuan-Xiu Liao
  • Patent number: 9951149
    Abstract: Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: April 24, 2018
    Assignees: The University of North Carolina at Chapel Hill, Rensselaer Polyechnic Institute, NUtech Ventures
    Inventors: Jian Liu, Yongmei Xu, Robert J. Linhardt, Edward Harris
  • Patent number: 9394379
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: July 19, 2016
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Patent number: 9364498
    Abstract: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: June 14, 2016
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Faiyaz Ahmed Hossainy, Ni Ding
  • Patent number: 9068957
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 30, 2015
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Nur Sibel Gunay, Miroslaw Lech, Sucharita Roy, John Schaeck, Jennifer Ozug, Daniela Beccati, Ishan Capila
  • Publication number: 20150147812
    Abstract: The present invention provides; a novel gene introduction method which enables a gene to be introduced more safely and more freely, particularly a method for introducing a gene into a specified site in the brain safely and freely; a carrier for gene introduction use, which comprises a nano-particle and a substance capable of binding to a vector for gene introduction and has functional groups involved in the induction of phagocytosis by cells, wherein the substance capable of binding to a vector for gene introduction can bind to the surface of the nano-particle through some of the functional groups and another some of the functional groups remain unbound to the substance capable of binding to a vector for gene introduction; and a gene introduction agent, in which a vector for gene introduction is bound to the substance capable of binding to a vector for gene introduction in the carrier for gene introduction.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 28, 2015
    Applicant: LSIP, LLC
    Inventors: Hiroshi Onodera, Hiroshi Handa, Satoshi Sakamoto, Mamoru Hatakeyama
  • Publication number: 20150118185
    Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Inventor: Paul L. DeAngelis
  • Patent number: 9018372
    Abstract: The invention relates to a bonding product comprising at least the polysaccharides T1 and T2, characterized in that a) the monosaccharides from which the polysaccharides T1 and T2 are constructed are partially or completely bonded to each other alpha-1,4-glycosidically and b) at least one of the polysaccharides T1 and/or T2 comprises at least one amino group and c) T1 and T2 are chemically bonded to each other covalently by at least one linker Z and d) T1 and/or T2 carries m groups -(L-A), wherein A is an active pharmaceutical ingredient and/or a fluorescence label, L is a second linker, by which T1 and/or T2 is covalently bonded to A, and m is an integer, which is 0 or at least 1.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: April 28, 2015
    Assignee: B. Braun Melsungen AG
    Inventors: Bernd Horst Meier, Iris Jankowiak-Meier, Nele Meier, Clara Meier
  • Publication number: 20150094460
    Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Inventors: Michio Muguruma, Hiroshi Murata
  • Patent number: 8986713
    Abstract: The present invention relates to immobilized biologically active entities that retain significant biological activity following mechanical manipulation of a substrate material to which the entities are immobilized.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: March 24, 2015
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Robert L. Cleek, Michael D. Daly, Krzysztof R. Pietrzak
  • Publication number: 20150072396
    Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.
    Type: Application
    Filed: March 1, 2012
    Publication date: March 12, 2015
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
  • Publication number: 20150037341
    Abstract: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.
    Type: Application
    Filed: February 21, 2012
    Publication date: February 5, 2015
    Applicant: Plysackaridforskning i Uppsala AB
    Inventors: Ulf Lindahl, Jin-ping Li, Fredrik Noborn
  • Publication number: 20150018537
    Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
    Type: Application
    Filed: April 18, 2014
    Publication date: January 15, 2015
    Applicant: Reliable Biopharmaceutical Corporation
    Inventors: Sourena NADJI, James T. Smoot, Joseph A. Vanartsdalen
  • Publication number: 20150011505
    Abstract: The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 8, 2015
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson
  • Publication number: 20140364369
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Application
    Filed: December 19, 2012
    Publication date: December 11, 2014
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • Publication number: 20140349962
    Abstract: The present invention provides methods for the production of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, compounds thus obtained and compositions comprising same. This invention also provides applications of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, and compositions comprising same, for use in controlling coagulation and treating thrombosis.
    Type: Application
    Filed: May 24, 2013
    Publication date: November 27, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Robert D. ROSENBERG, Kuberab BALAGURUNATHAN
  • Publication number: 20140336369
    Abstract: Processes are disclosed for the synthesis of the Factor Xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Applicant: APICORE US LLC
    Inventors: Ravishanker Kovi, Ashish Naik, Brijesh Patel, Muralikrishna Madala
  • Publication number: 20140315815
    Abstract: The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan.
    Type: Application
    Filed: October 18, 2012
    Publication date: October 23, 2014
    Inventors: Hubert Metzner, Sabine Zollner
  • Patent number: 8865681
    Abstract: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 21, 2014
    Assignee: Yissum Research Development Company of the Hebrew Unitersity of Jerusalem
    Inventors: Saul Yedgar, Yuval Cohen
  • Patent number: 8865878
    Abstract: This invention provides compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: October 21, 2014
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Publication number: 20140308272
    Abstract: According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG and/or HSPG.
    Type: Application
    Filed: January 17, 2014
    Publication date: October 16, 2014
    Applicant: Sylvan Pharmaceuticals Pty, Ltd.
    Inventors: John Fergus McEwan, David Cullis-Hill, Martin Lyndale Windsor
  • Patent number: 8822659
    Abstract: Procedure for the synthesis of deprotected pentasaccharides from a protected precursor pentasaccharide through a reaction procedure having five stages whereamong is included an N-sulphation of amino groups and a hydrogenolysis of benzyl groups. Through this procedure a drastic reduction is achieved in the total synthesis time in comparison with the process traditionally employed, together with increased reproducibility thereof, permitting the standardization thereof.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 2, 2014
    Assignee: Laboratorios Farmacéutios Rovi, S.A.
    Inventors: Ivan Lopez-Belmonte Encina, Rafael Ojeda Martinez De Castilla
  • Publication number: 20140221522
    Abstract: There is provided inter alia a substrate with a surface having a hydrophilic coating comprising a cross-linked copolymer of components A and B, and optional components C and D; wherein component A comprises one or more C2-C16 hydrophilic monomers each bearing one or more alkene and/or alkyne groups; component B comprises one or more hydrophilic polymers each bearing two or more alkene and/or alkyne groups; component C, if present, comprises one or more beneficial agents each bearing one or more alkene or alkyne groups; and component D, if present, comprises one or more low molecular weight cross-linking agents each bearing two or more functional groups independently selected from thiol, alkene and alkyne groups; wherein the cross-linked copolymer is formed by radical polymerisation involving the alkene and/or alkyne groups of components A, B and C (if present) and involving the functional groups of component D (if present); wherein the hydrophilic coating optionally comprises component E which comprises on
    Type: Application
    Filed: February 4, 2014
    Publication date: August 7, 2014
    Inventors: Per Antoni, Daniel Nystrom, Lars Vincent, Krzysztof Pietrzak
  • Publication number: 20140155497
    Abstract: Biomaterial compositions that include an isolated heparosan polymer are disclosed, as well as kits containing such biomaterial compositions and methods of producing and using such biomaterial compositions.
    Type: Application
    Filed: October 22, 2013
    Publication date: June 5, 2014
    Applicant: The Board of Regents of the University of Oklahoma
    Inventor: Paul L. DeAngelis
  • Patent number: 8742013
    Abstract: The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such as poly(ethylene oxide), poly(vinyl alcohol), or poly(vinyl pyrrolidone). The present disclosure also provides their synthesis methods, products of hydrogels and films using the same as and methods for manufacturing the products.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: June 3, 2014
    Assignee: Seoul National University of Technology Center for Industrial Collaboration
    Inventors: Insup Noh, Seongyeun Jo, Doyeon Kim, Junghoon Woo
  • Patent number: 8735363
    Abstract: The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: May 27, 2014
    Inventors: Peixue Ling, Yanli He, Jianying Chen
  • Publication number: 20140135486
    Abstract: A multi-arm polyethylene glycol (I) having different kinds of reactive groups and the uses thereof are disclosed, which is formed by polymerizing ethylene oxide with oligo-pentaerythritol as an initiator, wherein, PEG is same or different and is —(CH2CH2O)m—, the average value of m is an integer of 2-250; l is an integer of 1 or more. The method for producing the multi-arm polyethylene glycol having different kinds of reactive groups, the multi-arm polyethylene glycol active derivatives comprising linking groups X attached to PEG and terminal reactive groups F attached to X, the gels formed by the multi-arm polyethylene glycol active derivatives, the drug conjugates formed by the multi-arm polyethylene glycol active derivatives and drug molecules, and the uses thereof in preparing drugs are also disclosed.
    Type: Application
    Filed: January 21, 2014
    Publication date: May 15, 2014
    Applicant: JENKEM TECHNOLOGY CO., LTD, TIANJIN BRANCH
    Inventors: Xuan Zhao, Meina Lin
  • Publication number: 20140128544
    Abstract: The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: W. L. Gore & Associates, Inc.
    Inventors: Roy Biran, Charles D. Claude, Robert L. Cleek, Paul D. Drumheller
  • Patent number: 8715953
    Abstract: The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: May 6, 2014
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ganesh Kaundinya, Zachary Shriver, Mallikarjun Sundaram, Yi-wei Qi, Ram Sasisekharan
  • Publication number: 20140114056
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.
    Type: Application
    Filed: February 21, 2012
    Publication date: April 24, 2014
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Nur Sibel Gunay, Miroslaw Lech, Sucharita Roy, John Schaeck, Jennifer Ozug, Daniela Beccati, Ishan Capila
  • Patent number: 8691793
    Abstract: Described herein are compounds such as macromolecules that have been modified in order to facilitate crosslinking and methods of making and using thereof.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: April 8, 2014
    Assignee: University of Utah Research Foundation
    Inventors: Glenn D. Prestwich, Xiao Zheng Shu, Yanchun Liu
  • Patent number: 8663148
    Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: March 4, 2014
    Assignee: Exthera Medical Corporation
    Inventors: Olle Larm, Tomas Bergström, Jonas Axelsson, Lars Adolfsson, Robert S. Ward, Keith McCrea
  • Publication number: 20140045169
    Abstract: Disclosed are glycan immobilized metal nanoparticles and a method used thereof for detecting HIV-1 in a saliva sample at early stages of viral infection. The method comprises the steps of: (A) providing glycan immobilized metal nanoparticles which can recognize HIV-1; (B) contacting the glycan immobilized metal nanoparticles with the saliva sample and a mixture is obtained; (C) concentrating the mixture; and (D) determining HIV-1 in the concentrated mixture by an appropriate detecting method.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 13, 2014
    Applicant: SUDX LIFE SCIENCE CORP.
    Inventors: Yasuo SUDA, Masanori BABA, Mika OKAMOTO
  • Publication number: 20140031315
    Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 30, 2014
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
  • Publication number: 20140031316
    Abstract: The invention relates to sulphated polysaccharides which have the general structure of the constituent polysaccharides of heparin and which have a molecular weight of less than 8000 Daltons, comprising two antithrombin III-binding hexasaccharide sequences corresponding to formula (I) in which: R1 represents an OH group when the hexasaccharide of formula (I) is located at the reducing end of the polysaccharide, or else R1 represents a bond with another saccharide unit of said polysaccharide; R2 represents a hydrogen atom when the hexasaccharide of formula (I) is located at the non-reducing end of the polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit of said hexasaccharide is a double bond, or else R2 represents a bond with another saccharide unit of said polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit is a single bond.
    Type: Application
    Filed: April 11, 2012
    Publication date: January 30, 2014
    Applicant: SANOFI
    Inventors: Pierre Mourier, Christian Viskov
  • Publication number: 20130296540
    Abstract: Methods for preparing synthetic heparins are provided. Synthetic heparin compounds, including ultralow molecular weight heparin compounds are provided. Also provided are methods of chemoenzymatically synthesizing structurally homogeneous ultra-low molecular weight heparins. Heparin compounds provided herein can have anticoagulant activity.
    Type: Application
    Filed: December 22, 2011
    Publication date: November 7, 2013
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Yongmei Xu, Jian Liu
  • Patent number: 8557968
    Abstract: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: October 15, 2013
    Assignee: Sanofi
    Inventors: Philippe Duchaussoy, Jean Pascal Herault, Jean Marc Herbert, Maurice Petitou, Pierre Savi
  • Publication number: 20130261291
    Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
    Type: Application
    Filed: March 8, 2013
    Publication date: October 3, 2013
    Applicant: Reliable Biopharmaceutical Corporation
    Inventors: Payal Parth PATEL, Chun MA, Kevin K. OHRR, Sourena NADJI
  • Publication number: 20130259944
    Abstract: This disclosure relates to methods and compositions for treating cancer with platinum particles. In certain embodiments, the disclosure relates to platinum particle coated with a polysaccharide, such as a heparin or modified heparin, conjugated to a polypeptide that has affinity for a cell surface cancer marker and uses related thereto.
    Type: Application
    Filed: March 8, 2013
    Publication date: October 3, 2013
    Applicant: EMORY UNIVERSITY
    Inventors: Dong M. Shin, Shuming Nie, XiangHong Peng, Yiqing Wang
  • Patent number: 8546354
    Abstract: The instant invention relates to decasaccharides of formula (I): wherein Ac represents an acetyl group and R represents a group of formula —OH or —OSO3?, in their acid form or in the form of any one of their pharmaceutically acceptable salts, and to their process of preparation. The oligosaccharides of formula (I) are useful as antithrombotic agents.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: October 1, 2013
    Assignee: Sanofi
    Inventors: Pierre Mourier, Christian Viskov
  • Publication number: 20130244975
    Abstract: The present invention is related to compositions which can undergo targeted degradation under certain physiological reducing conditions. The compositions may, for example, be hydrogels in which maleimide-functionalized low molecular weight heparin is cross-linked with various thiol-functionalized polyethylene glycol multi-arm star polymers. Both the gelation and degradation of the hydrogels can be modified by careful selection of the thiol. For example, hydrogels prepared from aryl thiol-maleimide adducts can undergo a retro Michael addition-type reaction, leading to degradation of the composition and release of the bioactive molecule.
    Type: Application
    Filed: September 6, 2012
    Publication date: September 19, 2013
    Applicant: University of Delaware
    Inventors: Aaron Baldwin, Kristi Lynn Kiick
  • Patent number: 8536317
    Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: September 17, 2013
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • Patent number: 8518909
    Abstract: The instant invention relates to the heptasaccharide of formula (I): in its acid form or in the form of any one of its pharmaceutically acceptable salts, and to its process of preparation. The oligosaccharide of formula (I) is useful as an antithrombotic agent.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: August 27, 2013
    Assignee: Sanofi
    Inventors: Pierre Mourier, Christian Viskov
  • Publication number: 20130202549
    Abstract: The disubstituted piperazine analogs (DPAs) derivative compound and DPAs amine complex compound disclosed in the present aspects have characterized by presented pharmaceutics having functions to improve lipolysis, such as inhibiting obesity hyperlipidemia, and atherosclerosis.
    Type: Application
    Filed: September 6, 2012
    Publication date: August 8, 2013
    Inventor: Ing-Jun Chen
  • Patent number: 8501711
    Abstract: The instant invention relates to the decasaccharide of formula (I), wherein Ac represents an acetyl group: in its acid form or in the form of any one of its pharmaceutically acceptable salts, and to its process of preparation. The oligosaccharide of formula (I) is useful as an antithrombotic agent.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: August 6, 2013
    Assignee: Sanofi
    Inventors: Pierre Mourier, Christian Viskov
  • Publication number: 20130183764
    Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
    Type: Application
    Filed: September 13, 2011
    Publication date: July 18, 2013
    Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD., UNIVERSITY OF MIYAZAKI
    Inventors: Michio Muguruma, Hiroshi Murata
  • Publication number: 20130183254
    Abstract: Methods and compositions related to promoting hair growth are described.
    Type: Application
    Filed: June 15, 2011
    Publication date: July 18, 2013
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: He Zhou, Edward Cochran
  • Publication number: 20130156856
    Abstract: The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided.
    Type: Application
    Filed: November 6, 2012
    Publication date: June 20, 2013
    Applicant: Industrial Technology Research Institute
    Inventor: Industrial Technology Research Institute
  • Patent number: 8435795
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature that is indicative of the methods used to make the heparin preparation.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: May 7, 2013
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Sucharita Roy
  • Publication number: 20130102764
    Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 25, 2013
    Applicant: Reliable Biopharmaceutical Corporation
    Inventors: Sourena NADJI, James T. Smoot, Joseph A. Vanartsdalen